# A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

> **NCT06238466** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 98 (actual)

## Conditions studied

- Cardiovascular

## Interventions

- **DRUG:** AZD1705
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06238466
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-16
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-08-31
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238466, "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06238466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*